NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $96,745 — Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages A major goal of HIV-1 vaccine development is to induce broadly neutralizing antibodies (bnAbs). This IPCAVD team has immunogens that can trigger unmutate…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2021 · $214,021 — The Administrative Core A, led by Dr. Richard Wyatt, will administer support for Projects 1 and 2 and Cores B and C, under the umbrella of this new HIVRAD proposal. This Core will coordinate an administrative partnership plan to maintain good communications within the HIVRAD working group and releva…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
JOHN H. SAMPSON · DUKE UNIVERSITY · 2021 · $631,432 — PROJECT SUMMARY – Project 1 We recently reported in Nature that patients with glioblastoma (GBM) randomized to receive a vaccine against Cytomegalovirus (CMV) major integument protein pp65 using a tetanus/diphtheria (Td) vaccine site preconditioning regimen had a statistically significant increase i…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
THOMAS F GAJEWSKI · UNIVERSITY OF CHICAGO · 2021 · $221,729 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIM- cGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
George N. Pavlakis · DIVISION OF BASIC SCIENCES - NCI · 2021 · $1,158,141 — An important goal of this project continues to be the generation and testing of maximally efficient expression vectors for specific antigens. Our hypothesis is that the DNA vaccine dose is suboptimal for many human applications; therefore, increased efficiency is necessary for practical human DNA va…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
GIORGIO TRINCHIERI · DIVISION OF BASIC SCIENCES - NCI · 2021 · $694,605 — Progress has been made in several of the aims of the project. We studied the role of inflammatory receptors and cytokines in skin and colon chemical carcinogenesis. Signaling through the adaptor protein MyD88 promotes carcinogenesis in several cancer models. In contrast, MyD88 signaling has a protec…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $1,904,954 — ABSTRACT - Project 3 Coronaviruses havethe potential to cause significant morbidity andmortality as demonstrated by the ongoing SARS-CoV-2 pandemic. The purpose of this program project is to develop safe and broadly-protective group 2b and 2c betacoronavirus (panbetaCoV) vaccines capable of inducin…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
CHOWDA REDDY · NEOVAXSYN, INC. · 2021 · $300,000 — Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
PYONE AYE · TULANE UNIVERSITY OF LOUISIANA · 2021 · $918,112 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
JOHN H. SAMPSON · DUKE UNIVERSITY · 2021 · $565,025 — ABSTRACT We have previously reported in Nature that patients with newly-diagnosed glioblastoma (GBM) randomized to receiving vaccines against Cytomegalovirus (CMV) using a potent vaccine site preconditioning regimen had a statistically significant increase in progression-free survival (PFS) and over…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Dipak Kumar Raj · BROWN UNIVERSITY · 2021 · $406,250 — Project Summary The overall aim of this application is to advance PfCDPK5 and PfGARP as vaccine candidates for falciparum malaria. P.falciparum malaria affects almost one-half of the world's population and causes more than 500,000 deaths annually. Young children in malaria endemic areas of Africa h…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Rebecca Dutch · BOSTON UNIVERSITY MEDICAL CAMPUS · 2021 · $199,384 — SUMMARY Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are major causes of respiratory disease and hospitalization in infants. They are also a significant health concern for the elderly, the immunocompromised and individuals who have underlying lung disorders. RSV and HMPV are bo…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2021
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2021 · $376,438 — PROJECT SUMMARY/ABSTRACT High-risk human papillomaviruses (HR HPVs) cause 5% of all cancers. There are preventive vaccines against HPV, but less than 2% of the world's target population has received them. This leaves millions of women and men at risk for HPV-associated cervical, anogenital, and hea…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2023
Z Hong ZHOU · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $456,167 — Double-stranded RNA (dsRNA) viruses comprise a large group of non-enveloped viruses characterized by their ability to transcribe their RNA within an intact capsid (i.e., endogenous RNA transcription), thus evading cellular antiviral responses to dsRNA. Among them, members of the Reoviridae family of…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2023
Andrew Mehle · UNIVERSITY OF WISCONSIN-MADISON · 2023 · $685,427 — ABSTRACT Influenza virus is a serious public health threat causing high levels of morbidity and mortality. The annual disease burden from influenza places a significant strain on our healthcare infrastructure and economy. This is despite many efforts to control disease with yearly vaccination, antiv…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2023
Alkesh Harihar Jani · VA EASTERN COLORADO HEALTH CARE SYSTEM · 2023 — Bacterial infections are the second leading cause of death in ESRD. The incidence of pneumonia amongst dialysis patients is increasing and leads to a mortality rate that is 14-16-fold greater than pneumonia in the general population. Little is known regarding the immune response to pneumococcal vacc…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2023
Susan L Swain · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2023 · $251,250 — ABSTRACT: Harnessing Age-Associated B Cells for a Universal Influenza Vaccine for the Aged. With age, the generation of T follicular helpers from naive CD4 T cells, and germinal center B cells from follicular B cells, that are both needed for the generation of high affinity antibody (Ab), become hig…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2023
DANIEL G ANDERSON · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $785,418 — Many HIV vaccine candidates have failed clinical trials, as they were unable to elicit a potent and durable response to HIV viral challenge. Broadly neutralizing antibodies (bnAbs) have been identified in a number of HIV+ individuals with well-controlled viral levels, and these bnAbs target epitopes…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2023
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2023 · $3,402,658 — Neutralizing antibodies are likely to be required for an effective HIV-1 vaccine. However, few candidate vaccines efficiently elicit broadly neutralizing antibodies (bNAbs) following vaccination. Recently, the VRC working group has elicited fusion peptide-directed bNAbs in guinea pigs and non-human …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2023
LAURA CONFORTI · UNIVERSITY OF CINCINNATI · 2023 · $189,338 — PROJECT SUMMARY Immune checkpoint inhibitors like monoclonal blocking antibodies against programmed cell death 1 (PD1) have revolutionized the way solid malignancies are treated. However, despite a dramatic response in some patients, the majority either have no response or develop resistance. The fo…